Walsartan w codziennej praktyce klinicznej – o czym trzeba pamiętać? Opis serii przypadków
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2013
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Szymański , F. M. (2013). Walsartan w codziennej praktyce klinicznej – o czym trzeba pamiętać? . Medycyna Faktów , 6(1(18), 63-68. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2430
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Vestbo J., Hurd S.S., Agustí A.G. et al.: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2013; 187: 347-365.
2. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension 2011; 15: 55-82.
3. Nixon R.M., Müller E., Lowy A., Falve et al.: Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 2009; 63: 766-775.
4. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
5. Sawada T., Yamada H., Dahlöf B., Matsubara H.; KYOTO HEART Study Group: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
6. The NAVIGATOR Study Group: Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N. Engl. J. Med. 2010; 362: 1477-1490.
7. Manfredini R., Gallerani M., Portaluppi F. et al.: Chronobiological patterns of onset of acute cerebrovascular diseases. Thromb. Res. 1997; 88: 451-463.
8. Li Y., Thijs L., Hansen T.W. et al.: The International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. Hypertension 2010; 55: 1040-1048.
9. Kario K., Pickering T.G., Matsuo T. et al.: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-857.
10. Hermida R.C., Calvo C., Ayala D.E. et al.: Treatment of non-dipper hypertension with bedtime administration of valsartan. J. Hypertens. 2005; 23: 1913-1922.
11. Dong J.Y., Zhang Y.H., Qin L.Q.: Erectile dysfunction and risk of cardiovascular disease. Meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 2011; 58: 1378-1385.
12. Grimm R.H., Grandits G.A., Prineas R.J. et al.: Longterm effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997; 29: 8-14.
13. Jackson G., Boon N., Eardley I. et al.: Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Clin. Pract. 2010; 64: 848-857.
14. Fabbri L.M., Luppi F., Beghé B., Rabe K.F.: Complex chronic comorbidities of COPD. Eur. Respir J. 2008; 31: 204-212.
2. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertension 2011; 15: 55-82.
3. Nixon R.M., Müller E., Lowy A., Falve et al.: Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 2009; 63: 766-775.
4. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
5. Sawada T., Yamada H., Dahlöf B., Matsubara H.; KYOTO HEART Study Group: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur. Heart J. 2009; 30: 2461-2469.
6. The NAVIGATOR Study Group: Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N. Engl. J. Med. 2010; 362: 1477-1490.
7. Manfredini R., Gallerani M., Portaluppi F. et al.: Chronobiological patterns of onset of acute cerebrovascular diseases. Thromb. Res. 1997; 88: 451-463.
8. Li Y., Thijs L., Hansen T.W. et al.: The International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations. Hypertension 2010; 55: 1040-1048.
9. Kario K., Pickering T.G., Matsuo T. et al.: Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852-857.
10. Hermida R.C., Calvo C., Ayala D.E. et al.: Treatment of non-dipper hypertension with bedtime administration of valsartan. J. Hypertens. 2005; 23: 1913-1922.
11. Dong J.Y., Zhang Y.H., Qin L.Q.: Erectile dysfunction and risk of cardiovascular disease. Meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 2011; 58: 1378-1385.
12. Grimm R.H., Grandits G.A., Prineas R.J. et al.: Longterm effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women: treatment of mild hypertension study (TOMHS). Hypertension 1997; 29: 8-14.
13. Jackson G., Boon N., Eardley I. et al.: Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int. J. Clin. Pract. 2010; 64: 848-857.
14. Fabbri L.M., Luppi F., Beghé B., Rabe K.F.: Complex chronic comorbidities of COPD. Eur. Respir J. 2008; 31: 204-212.